Clinical Trials
10 trialsNCT04164199 2026-06-03
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Completed
NCT04539444 2026-06-02
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Completed
NCT07619937 2026-06-02
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
NCT05542342 2026-06-01
SITISVEAL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT06010303 2026-05-28
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 2 Completed
NCT05519865 2026-04-20
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Phase 2 Completed
NCT06233981 2026-04-17
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT03744468 2026-04-02
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
Phase 1/2 Completed
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed